Sign in

Research summary ·

Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This review looked at a drug called deutetrabenazine for Tourette syndrome. In Tourette syndrome, people have movement and voice tics. The team searched for trials up to October 2025. Each trial gave people either the drug or a dummy pill. The team pooled the results of these trials, with 297 people in all.

What they found

The drug lowered tic scores more than the dummy pill did. The authors call this gain modest. The trials gave similar results on this test. There was no clear gain in overall doctor or patient ratings. Quality of life and low mood also showed no clear change. Side effects were not clearly more common with the drug.

What it means for patients

The authors say the drug lowers tics by a modest amount. They say its safety looked good. But fewer tics did not lead to better scores in other areas. They see it as a possible add-on drug for some patients. They also say care should mix several kinds of help.

Why it is not certain yet

Only 297 people took part across all the trials. The gain in tic scores was modest. Other results showed no clear benefit. The authors say longer studies are still needed. A review can only be as good as the studies in it.

Source

Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

PubMed · PMID 42267238

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Tourette syndrome publications